**Bijoy Hans Limited (BHL)** is currently undergoing a transformative strategic pivot following a change in management control in **July 2025**. Historically a trader of bulk drugs and cosmetics, the company is transitioning into a technology-enabled, integrated healthcare provider. This evolution involves a complete rebranding, a shift in geographic focus, and a series of aggressive inorganic acquisitions designed to create a "smart" healthcare ecosystem. --- ### Strategic Transformation & Rebranding The company is moving away from its legacy trading roots to adopt a high-tech healthcare model. To reflect this new identity, BHL is in the process of changing its name to **Arvaya Healthcare Limited**. **Key Pillars of the New Strategy:** * **Integrated Ecosystem:** Merging hospital management, diagnostic services, and wellness clinics under a single brand. * **Technology-First Approach:** Leveraging **AI**, **IoT**, **Blockchain**, and **Data Analytics** to improve clinical outcomes and operational efficiency. * **Affordability & Accessibility:** Focusing on technology-driven solutions to provide scalable healthcare services. * **Geographic Realignment:** Shifting the corporate headquarters from **Guwahati, Assam** to **Maharashtra** to streamline management and administrative operations. --- ### Core Business Verticals & Service Delivery The company operates across five primary segments, integrating physical infrastructure with digital platforms. | Segment | Scope of Operations | | :--- | :--- | | **Healthcare Services** | Multi-specialty hospitals, diagnostic centers, pathological labs, and blood banks. Specialties include **Cardiac Sciences, Oncology, Nephrology, and Neonatology**. | | **Digital Health** | App-based teleconsultations, remote patient monitoring, **Tele-ICU support**, and e-pharmacy delivery. | | **Hospitality** | Smart hotels, resorts, and serviced apartments integrated with **AI-enabled Property Management Software (PMS)**. | | **Wellness & Fitness** | Spas, yoga studios, and physiotherapy centers featuring **biometric monitoring** and digital tracking. | | **Consultancy & R&D** | Hospital administration advisory, digital transformation services, and R&D in medical devices/software. | **Service Delivery Models:** * **Physical Infrastructure:** Construction and management of tech-enabled hospitals and wellness retreats. * **At-Home Care:** Home sample collection, virtual fitness sessions, and technology-driven home healthcare. * **B2B Advisory:** Providing skill development and professional consultancy to third-party healthcare entities. --- ### Inorganic Growth: Strategic Acquisitions BHL has utilized share swaps and cash to acquire key entities, turning them into **Wholly Owned Subsidiaries** to build its vertical capabilities. * **Health Secure Hospitals Pvt Ltd (HSHPL):** Acquired for **₹19.40 Cr** (via **1,55,21,967** shares) plus **₹10 Cr** cash. This provides the core clinical infrastructure. * **Arvaya Health and Wellness Pvt Ltd (AHWPL):** Acquired for **₹18.75 Cr** (via **1,49,99,990** shares) to lead the preventive and rehabilitative wellness segment. * **Tec-Pool Solutions Pvt Ltd (TPSPL):** Acquired for **₹12.50 Cr** (via **99,99,879** shares) to serve as the technology backbone for data analytics and process automation. * **Koppal Unit:** Successful transfer of the entire business undertaking to BHL operations. --- ### Capital Structure & Financial Health To fund this massive expansion, the company has significantly overhauled its financial capacity. **Capital Expansion:** * **Authorized Share Capital:** Increased from **₹10 Cr** to **₹60 Cr** in late 2025, with a further proposal to reach **₹200 Cr** by **March 2026**. * **Borrowing & Investment Limits:** Enhanced to **₹200 Cr** under Section 186 to facilitate CAPEX and subsidiary investments. * **Recent Funding:** Raised **₹5.62 Cr** via a preferential allotment of **45,00,000** shares at **₹12.50** per share in **May 2025**. As of **Q3 FY2026**, there is **NIL deviation** in the use of these proceeds. **Financial Position:** * **Profitability:** The company has faced historical **cash losses** (**₹38.53 Lakhs** in FY2023 vs **₹15.33 Lakhs** in FY2022). * **Solvency:** Management and auditors confirm no material uncertainty regarding the ability to meet liabilities within a **12-month** horizon. * **Debt:** No outstanding indebtedness or contingent liabilities outside the ordinary course of business. --- ### Operational Infrastructure & Regulatory Compliance The company maintains a complex web of licenses across **Karnataka** and **Maharashtra** to support its multi-state operations. | Category | Regulatory Framework / License | | :--- | :--- | | **Clinical** | **Karnataka Private Medical Establishments Act**; **Maharashtra Nursing Homes Registration Act** | | **Pharma** | Retail and wholesale licenses under **Drugs and Cosmetics Act, 1940** | | **Specialized** | **PNDT Act** (Ultrasound); **Atomic Energy Act** (Imaging); **Human Organs Transplantation Act** | | **Environment** | **Bio-Medical Waste Management Rules, 2016**; Water and Air Pollution Consents | --- ### Leadership & Corporate Governance Following the **2025 Open Offer**, control was assumed by a new promoter group led by **Mr. Kaushal Uttam Shah**. * **Management:** **Mr. Kaushal Uttam Shah** serves as **Chairman and Managing Director** (2025–2030). **Mr. Salil Shetty** will join as **CEO** on **April 1, 2026**, to lead product strategy. * **Promoter Reclassification:** The erstwhile promoters (the **Patwari family**) have sought reclassification to the **'Public'** category. * **Listing Status:** Listed on the **BSE** (**Scrip Code: 524723**). The company is voluntarily delisting from the **Calcutta Stock Exchange (CSE)**. --- ### Risk Factors & Mitigation Investors should note several structural and transitional risks: **1. Market & Competition:** * **Stagnant Demand:** The pharmaceutical trading industry faces low growth and intense price pressure from **China**. * **Concentration Risk:** Historically operated in a single segment, though the pivot to healthcare aims to diversify this. **2. Compliance Gaps:** * **Historical Deficiencies:** Past failures in filing **Significant Beneficial Ownership (SBO)** forms and delays in **ESI/PF** filings at the **Solapur Unit**. * **Environmental Filings:** Pending **Form IV** filings for units in **Mysuru, Chikkamagaluru, and Gadag**. **3. Transition & Transactional Risks:** * **Public Float:** If public shareholding drops below **25.00%**, the company must dilute promoter stakes within **12 months** to comply with SEBI mandates. * **Indemnities:** Potential revenue leakage or tax liabilities related to the migration of government empanelments from **Hubli Secure Multi Speciality Hospital LLP**. * **Restrictive Covenants:** Non-compete agreements limit the company from engaging with certain competing facilities for **6 months** post-engagement. **4. Related Party Transactions (RPT):** The company recently disposed of legacy assets (office property, cars, and furniture) to the outgoing promoters at **Market Rate** or **Written Down Value (WDV)** to clean the balance sheet for the new healthcare operations. Hospital premises are currently leased from **Secure Hospitals Private Limited** at an annual rent of **₹19.20 Lakhs**.